| Year |
Citation |
Score |
| 2020 |
Batumalai V, Delaney GP, Descallar J, Gabriel G, Wong K, Shafiq J, Barton M. Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 32721419 DOI: 10.1016/J.Radonc.2020.07.038 |
0.346 |
|
| 2020 |
Barton M, Batumalai V, Spencer K. Health Economic and Health Service Issues of Palliative Radiotherapy. Clinical Oncology (Royal College of Radiologists (Great Britain)). PMID 32646615 DOI: 10.1016/J.Clon.2020.06.013 |
0.378 |
|
| 2020 |
Panozzo S, Le B, Collins A, Weil J, Whyte J, Barton M, Coperchini M, Rametta M, Philip J. Who is asking about medicinal cannabis in palliative care? Internal Medicine Journal. 50: 243-246. PMID 32037714 DOI: 10.1111/Imj.14732 |
0.312 |
|
| 2020 |
Yap ML, O'Connell DL, Goldsbury D, Weber M, Barton M. Factors Associated With Radiotherapy Utilisation In New South Wales, Australia: Results From The 45 and Up Study. Clinical Oncology (Royal College of Radiologists (Great Britain)). PMID 32007353 DOI: 10.1016/J.Clon.2020.01.007 |
0.344 |
|
| 2019 |
Merie R, Gabriel G, Shafiq J, Vinod S, Barton M, Delaney GP. Radiotherapy underutilisation and its impact on local control and survival in New South Wales, Australia. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 31606225 DOI: 10.1016/J.Radonc.2019.09.012 |
0.32 |
|
| 2019 |
Sarfati D, Dyer R, Sam FA, Barton M, Bray F, Buadromo E, Ekeroma A, Foliaki S, Fong J, Herman J, Huggins L, Maoate K, Meredith I, Mola G, Palafox N, et al. Cancer control in the Pacific: big challenges facing small island states. The Lancet. Oncology. PMID 31395476 DOI: 10.1016/S1470-2045(19)30400-0 |
0.365 |
|
| 2019 |
Spence D, Dyer R, Andall-Brereton G, Barton M, Stanway S, Argentieri MA, Bray F, Cawich S, Edwards-Bennett S, Fosker C, Gabriel O, Greaves N, Hanchard B, Hospedales J, Luciani S, et al. Cancer control in the Caribbean island countries and territories: some progress but the journey continues. The Lancet. Oncology. PMID 31395473 DOI: 10.1016/S1470-2045(19)30512-1 |
0.358 |
|
| 2019 |
Pham TT, Stait-Gardner T, Lee CS, Barton M, Graham PL, Liney G, Wong K, Price WS. Correlation of ultra-high field MRI with histopathology for evaluation of rectal cancer heterogeneity. Scientific Reports. 9: 9311. PMID 31249325 DOI: 10.1038/S41598-019-45450-2 |
0.314 |
|
| 2019 |
Batumalai V, Wong K, Shafiq J, Hanna TP, Gabriel G, Heberle J, Koprivic I, Kaadan N, King O, Tran T, Cassapi L, Forstner D, Delaney GP, Barton M. Estimating the cost of radiotherapy for 5-year local control and overall survival benefit. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 136: 154-160. PMID 31015119 DOI: 10.1016/J.Radonc.2019.04.011 |
0.307 |
|
| 2019 |
Gabriel G, Barton M, Shafiq J, Delaney G. OC-0158 Effect of EBRT underutilization in prostate cancer on overall survival and local control, NSW, Australia Radiotherapy and Oncology. 133. DOI: 10.1016/S0167-8140(19)30578-X |
0.304 |
|
| 2018 |
Do V, Ng W, Jacob S, Delaney G, Barton M. An estimation of the population-based survival benefit of first-course chemotherapy for advanced incurable cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: ix111. PMID 32177734 DOI: 10.1093/Annonc/Mdy440.006 |
0.348 |
|
| 2018 |
Batumalai V, Shafiq J, Gabriel G, Hanna TP, Delaney GP, Barton M. Impact of radiotherapy underutilisation measured by survival shortfall, years of potential life lost and disability-adjusted life years lost in New South Wales, Australia. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 29983259 DOI: 10.1016/J.Radonc.2018.06.026 |
0.321 |
|
| 2018 |
Pham T, Liney G, Wong K, Henderson C, Shin JS, Rai R, Lee M, Graham P, Hudson HM, Borok N, Truong M, Barton M. PO-0792: Rectal cancer: multiparametric MRI assessment of tumour heterogeneity and chemoradiotherapy response Radiotherapy and Oncology. 127. DOI: 10.1016/S0167-8140(18)31102-2 |
0.319 |
|
| 2018 |
Oar A, Vinod S, Gabriel G, Shafiq J, Barton M, Delaney G. P1.15-25 Has Lung Cancer Radiotherapy Utilisation Changed over Time in New South Wales, Australia? Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.957 |
0.303 |
|
| 2017 |
Pham TT, Liney G, Wong K, Rai R, Lee M, Moses D, Henderson C, Lin M, Shin JS, Barton MB. Study protocol: multi-parametric magnetic resonance imaging for therapeutic response prediction in rectal cancer. Bmc Cancer. 17: 465. PMID 28676107 DOI: 10.1186/S12885-017-3449-4 |
0.301 |
|
| 2017 |
Pham TT, Liney GP, Wong K, Barton MB. Review Article: Functional MRI for Quantitative Treatment Response Prediction in Locally Advanced Rectal Cancer. The British Journal of Radiology. 20151078. PMID 28055248 DOI: 10.1259/Bjr.20151078 |
0.341 |
|
| 2017 |
Do V, Ng W, Jacob S, Delaney GP, Barton M. 1088PAn estimation of the population survival benefit of first-course chemotherapy for head and neck cancers Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx374.043 |
0.348 |
|
| 2016 |
Yap ML, Zubizarreta E, Bray F, Ferlay J, Barton M. Global Access to Radiotherapy Services: Have We Made Progress During the Past Decade? Journal of Global Oncology. 2: 207-215. PMID 28717703 DOI: 10.1200/Jgo.2015.001545 |
0.362 |
|
| 2016 |
Yap ML, Hanna TP, Shafiq J, Ferlay J, Bray F, Delaney GP, Barton M. The Benefits of Providing External Beam Radiotherapy in Low- and Middle-income Countries. Clinical Oncology (Royal College of Radiologists (Great Britain)). PMID 27916340 DOI: 10.1016/J.Clon.2016.11.003 |
0.404 |
|
| 2016 |
Rodin D, Hanna TP, Burger E, Zubizarreta E, Yap ML, Barton MB, Atun R, Knaul F, Van Dyk J, Lievens Y, Gospodarowicz M, Jaffray DA, Milosevic M. Global Access to Radiation Therapy for Cervical Cancer: The Cost of Inaction. International Journal of Radiation Oncology, Biology, Physics. 96: S14-S15. PMID 27675622 DOI: 10.1016/J.Ijrobp.2016.06.049 |
0.32 |
|
| 2016 |
Borras JM, Lievens Y, Barton M, Corral J, Ferlay J, Bray F, Grau C. How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 26922487 DOI: 10.1016/J.Radonc.2016.02.016 |
0.395 |
|
| 2016 |
Rodin D, Hanna TP, Burger E, Zubizarreta E, Yap ML, Barton M, Atun R, Knaul F, Dyk JV, Lievens Y, Gospodarowicz M, Jaffray D, Milosevic M. 11: Global Access to Radiotherapy for Cervical Cancer: The Cost of Inaction Radiotherapy and Oncology. 120. DOI: 10.1016/S0167-8140(16)33410-7 |
0.322 |
|
| 2016 |
Whelan B, Welgampola M, McGarvie L, Makhija K, Feain I, Holloway L, Berry M, Barton M, Turner R, Jackson M, Keall P. EP-1930: Cancer patient experience of slow, single arc rotation to simplify radiation therapy delivery Radiotherapy and Oncology. 119: S916. DOI: 10.1016/S0167-8140(16)33181-4 |
0.334 |
|
| 2016 |
Pham T, Liney G, Wong K, Roach D, Moses D, Henderson C, Lee M, Rai R, Barton M. EP-1857: Multi-parametric MRI at 3.0 Tesla for the prediction of treatment response in rectal cancer Radiotherapy and Oncology. 119. DOI: 10.1016/S0167-8140(16)33108-5 |
0.312 |
|
| 2016 |
Borras JM, Lievens Y, Barton M, Corral J, Ferlay J, Bray F, Grau C. Symposium with Proffered Papers: Uncovering the gap between optimal and actual utilisation of radiotherapy in EuropeOC-0331: How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis Radiotherapy and Oncology. 119. DOI: 10.1016/S0167-8140(16)31580-8 |
0.384 |
|
| 2015 |
Gabriel G, Barton M, Delaney GP. The effect of travel distance on radiotherapy utilization in NSW and ACT. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 117: 386-9. PMID 26243679 DOI: 10.1016/J.Radonc.2015.07.031 |
0.382 |
|
| 2015 |
Rosenblatt E, Barton M, Mackillop W, Fidarova E, Cordero L, Yarney J, Lim G, Abad A, Cernea V, Stojanovic-Rundic S, Strojan P, Kobachi L, Quarneti A. Optimal radiotherapy utilisation rate in developing countries: An IAEA study. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 116: 35-7. PMID 26164776 DOI: 10.1016/J.Radonc.2015.06.012 |
0.342 |
|
| 2015 |
Kang YJ, O'Connell DL, Tan J, Lew JB, Demers A, Lotocki R, Kliewer EV, Hacker NF, Jackson M, Delaney GP, Barton M, Canfell K. Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada: Results from two large cancer facilities. Cancer Epidemiology. PMID 26004990 DOI: 10.1016/J.Canep.2015.04.009 |
0.398 |
|
| 2015 |
Borras JM, Barton M, Grau C, Corral J, Verhoeven R, Lemmens V, van Eycken L, Henau K, Primic-Zakelj M, Strojan P, Trojanowski M, Dyzmann-Sroka A, Kubiak A, Gasparotto C, Defourny N, et al. The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 116: 45-50. PMID 26002304 DOI: 10.1016/J.Radonc.2015.04.021 |
0.369 |
|
| 2015 |
Borras JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Corral J, Gasparotto C, Defourny N, Barton M, Verhoeven R, van Eycken L, Primic-Zakelj M, Trojanowski M, Strojan P, Grau C. The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 116: 38-44. PMID 25981052 DOI: 10.1016/J.Radonc.2015.04.018 |
0.384 |
|
| 2015 |
Sitas F, Yap S, Egger S, Christian K, Hodgkinson V, Barton M, Banks E, Canfell K, O'Connell DL, Nair-Shalliker V. The Cancer, Lifestyle and Evaluation of Risk Study (CLEAR): Rationale and design of an unmatched "case-spouse control" study of over 10,000 participants in New South Wales, Australia. Cancer Epidemiology. 39: 414-23. PMID 25892705 DOI: 10.1016/J.Canep.2015.03.006 |
0.33 |
|
| 2015 |
Ng W, Jacob S, Delaney G, Do V, Barton M. Estimation of an optimal chemotherapy utilisation rate for upper gastrointestinal cancers: setting an evidence-based benchmark for the best-quality cancer care. Gastroenterology Research and Practice. 2015: 753480. PMID 25883645 DOI: 10.1155/2015/753480 |
0.39 |
|
| 2015 |
Do V, Ng W, Jacob S, Delaney G, Barton M. 133Pan Estimation Of The Population-Based Survival Benefit Of First-Line Chemotherapy For Lung Cancer Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv050.37 |
0.32 |
|
| 2015 |
Atun R, Jaffray D, Barton M, Baumann M, Vikram B, Bray F, Hanna T, Knaul F, Lievens Y, O'Sullivan B, Rodin D, Dyke JV, Rosenblatt E, Yap M, Zubizarreta E, et al. 2LBA Responding to the cancer crisis: Expanding global access to radiotherapy - a Lancet Oncology Commission European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31925-6 |
0.372 |
|
| 2015 |
Do V, Ng W, Jacob S, Delaney G, Barton M. 2596 An estimation of population-based survival benefit of first-line chemotherapy for urological cancer European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31414-9 |
0.33 |
|
| 2014 |
Do V, Ng W, Delaney G, Barton M. 606PAN ESTIMATION OF THE POPULATION SURVIVAL BENEFIT OF FIRST-LINE CHEMOTHERAPY FOR GASTROINTESTINAL CANCER. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv206-iv207. PMID 28172241 DOI: 10.1093/Annonc/Mdu333.107 |
0.389 |
|
| 2013 |
Goldsbury D, Harris M, Pascoe S, Barton M, Olver I, Spigelman A, Beilby J, Veitch C, Weller D, O'Connell DL. The varying role of the GP in the pathway between colonoscopy and surgery for colorectal cancer: a retrospective cohort study. Bmj Open. 3. PMID 23471608 DOI: 10.1136/Bmjopen-2012-002325 |
0.308 |
|
| 2012 |
Goldsbury D, Harris MF, Pascoe S, Olver I, Barton M, Spigelman A, O'Connell D. Socio-demographic and other patient characteristics associated with time between colonoscopy and surgery, and choice of treatment centre for colorectal cancer: a retrospective cohort study. Bmj Open. 2. PMID 22637491 DOI: 10.1136/Bmjopen-2012-001070 |
0.347 |
|
| 2011 |
Christie D, Dear K, Le T, Barton M, Wirth A, Porter D, Roos D, Pratt G. Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. International Journal of Radiation Oncology, Biology, Physics. 80: 1164-70. PMID 20638196 DOI: 10.1016/J.Ijrobp.2010.03.036 |
0.337 |
|
| 2010 |
Arnold A, Delaney GP, Cassapi L, Barton M. The use of categorized time-trend reporting of radiation oncology incidents: a proactive analytical approach to improving quality and safety over time. International Journal of Radiation Oncology, Biology, Physics. 78: 1548-54. PMID 20598456 DOI: 10.1016/J.Ijrobp.2010.02.029 |
0.31 |
|
| 2010 |
Morgan G, Barton M, Atkinson C, Millar J, Gogna NK, Yeoh E. 'GAP' in radiotherapy services in Australia and New Zealand in 2009. Journal of Medical Imaging and Radiation Oncology. 54: 287-297. PMID 20598017 DOI: 10.1111/J.1754-9485.2010.02172.X |
0.357 |
|
| 2010 |
Ng WL, Jacob S, Delaney G, Barton M. Optimal chemotherapy utilization rate in cancer care: Setting an evidence-based benchmark for quality improvement. Journal of Clinical Oncology. 28: 6099-6099. DOI: 10.1200/Jco.2010.28.15_Suppl.6099 |
0.354 |
|
| 2010 |
Fong A, Shafiq J, Saunders C, Thompson A, Tyldesley S, Barton M, Dewar J, Ng W, Jacob S, Speers C, Olivotto I, Delaney G. Abstract P3-11-11: A Comparison of Breast Cancer Treatment Rates in British Columbia, Scotland, and Western Australia, and a Comparison with Models of “Optimal” Therapy Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-11-11 |
0.323 |
|
| 2010 |
Delaney GP, Fong A, Shafiq J, Olivotto IA, Tyldesley S, Saunders C, Thompson A, Barton M. A Comparison of Breast Cancer Radiotherapy Treatment Rates in British Columbia, Scotland, and Western Australia, and a Comparison with Models of “Optimal” Therapy International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.592 |
0.342 |
|
| 2009 |
Morgan G, Barton M, Crossing S, Bull C, Penman A. A 'Catch Up' Plan for radiotherapy in New South Wales to 2012. Journal of Medical Imaging and Radiation Oncology. 53: 419-30. PMID 19695050 DOI: 10.1111/J.1754-9485.2009.02098.X |
0.348 |
|
| 2009 |
Ng W, Jacob S, Delaney G, Barton M. Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care. European Journal of Cancer (Oxford, England : 1990). 45: 2150-9. PMID 19285857 DOI: 10.1016/J.Ejca.2009.02.007 |
0.388 |
|
| 2008 |
Ng WL, Delaney G, Jacob S, Barton M. Optimal chemotherapy utilisation rate in breast cancer: setting an evidence-based benchmark for the best-quality cancer care. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 6613. PMID 27949694 DOI: 10.1200/Jco.2008.26.15_Suppl.6613 |
0.367 |
|
| 2008 |
Thompson SR, Delaney G, Gabriel GS, Jacob S, Das P, Barton M. Estimation of optimal brachytherapy utilization rate in the treatment of malignancies of the uterine corpus by a review of clinical practice guidelines and the primary evidence. International Journal of Radiation Oncology, Biology, Physics. 72: 849-58. PMID 18448273 DOI: 10.1016/J.Ijrobp.2008.01.022 |
0.341 |
|
| 2008 |
Delaney G, Shafiq J, Chappell G, Barton M. Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines. Cancer. 112: 1912-22. PMID 18318431 DOI: 10.1002/Cncr.23384 |
0.379 |
|
| 2008 |
Gabriel GS, Lah M, Barton M, Au G, Delaney G, Jalaludin B. Do cancer follow-up consultations create anxiety? Journal of Psychosocial Oncology. 26: 17-30. PMID 18077260 DOI: 10.1300/J077V26N01_02 |
0.328 |
|
| 2007 |
Hegi-Johnson F, Gabriel G, Kneebone A, Wong C, Jalaludin B, Behan S, Barton M. Utilization of radiotherapy for rectal cancer in Greater Western Sydney 1994–2001 Asia-Pacific Journal of Clinical Oncology. 3: 134-142. DOI: 10.1111/J.1743-7563.2007.00100.X |
0.365 |
|
| 2007 |
Jacob S, Hovey E, Vinod S, Delaney G, Barton M. 1217 POSTER Estimation of an optimal chemotherapy utilisation rate for lung cancer Ejc Supplements. 5: 165-166. DOI: 10.1016/S1359-6349(07)70698-5 |
0.334 |
|
| 2006 |
Thompson S, Delaney G, Gabriel GS, Jacob S, Das P, Barton M. Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix: review of clinical practice guidelines and primary evidence. Cancer. 107: 2932-41. PMID 17109449 DOI: 10.1002/Cncr.22337 |
0.321 |
|
| 2006 |
Delaney G, Jacob S, Barton M. Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines. Cancer. 106: 453-65. PMID 16355366 DOI: 10.1002/Cncr.21596 |
0.344 |
|
| 2005 |
Wirth A, Yuen K, Barton M, Roos D, Gogna K, Pratt G, Macleod C, Bydder S, Morgan G, Christie D. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 104: 1221-9. PMID 16094666 DOI: 10.1002/Cncr.21303 |
0.307 |
|
| 2005 |
Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 104: 1129-37. PMID 16080176 DOI: 10.1002/Cncr.21324 |
0.438 |
|
| 2005 |
Back M, Ahern, Berry MP, Borg M, Sexton MJ, Cameron F, Stevens G, Allison R, Childs J, Barton M. Importance of radiation time and dose factors on outcome for childhood medulloblastoma. Journal of Medical Imaging and Radiation Oncology. 49: 298-303. PMID 16026436 DOI: 10.1111/J.1440-1673.2005.01468.X |
0.309 |
|
| 2005 |
Delaney G, Jacob S, Barton M. Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma. Cancer. 103: 2216-27. PMID 15856428 DOI: 10.1002/Cncr.21084 |
0.349 |
|
| 2005 |
Delaney G, Jacob S, Barton M. Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies. Cancer. 103: 462-73. PMID 15612081 DOI: 10.1002/Cncr.20789 |
0.427 |
|
| 2005 |
Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part I-lymphoma. Cancer. 103: 383-92. PMID 15599937 DOI: 10.1002/Cncr.20754 |
0.404 |
|
| 2005 |
Featherstone C, Delaney G, Jacob S, Barton M. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma. Cancer. 103: 393-401. PMID 15593373 DOI: 10.1002/Cncr.20755 |
0.377 |
|
| 2005 |
Estall V, Vinod S, Barton M. PD-108 Patterns of radiotherapy re-treatment in lung cancer patients:A retrospective, longitudinal study Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)80441-6 |
0.303 |
|
| 2004 |
Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clinical Oncology (Royal College of Radiologists (Great Britain)). 16: 549-60. PMID 15630849 DOI: 10.1016/J.Clon.2004.06.007 |
0.351 |
|
| 2004 |
Starmer D, Jamrozik K, Barton M, Miles S. Evaluating curriculum changes in undergraduate cancer education. Journal of Cancer Education : the Official Journal of the American Association For Cancer Education. 19: 156-60. PMID 15458870 DOI: 10.1207/S15430154Jce1903_9 |
0.341 |
|
| 2004 |
Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium. Cancer. 101: 682-92. PMID 15305397 DOI: 10.1002/Cncr.20445 |
0.408 |
|
| 2004 |
Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I--malignancies of the cervix, ovary, vagina and vulva. Cancer. 101: 671-81. PMID 15305396 DOI: 10.1002/Cncr.20444 |
0.395 |
|
| 2004 |
Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence. Cancer. 101: 657-70. PMID 15305395 DOI: 10.1002/Cncr.20443 |
0.349 |
|
| 2004 |
Lehman M, Jacob S, Delaney G, Papadatos G, Jalaludin B, Cail S, McCourt J, Wright S, O'Brien C, Barton M. Waiting times for radiotherapy--a survey of patients' attitudes. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 70: 283-9. PMID 15064014 DOI: 10.1016/J.Radonc.2004.01.012 |
0.347 |
|
| 2004 |
Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for melanoma: a review of the evidence. Cancer. 100: 1293-301. PMID 15022299 DOI: 10.1002/Cncr.20092 |
0.371 |
|
| 2003 |
Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for breast carcinoma: a review of the evidence. Cancer. 98: 1977-86. PMID 14584082 DOI: 10.1002/Cncr.11740 |
0.348 |
|
| 2003 |
Delaney G, Barton M, Jacob S, Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. The Lancet. Oncology. 4: 120-8. PMID 12573354 DOI: 10.1016/S1470-2045(03)00984-7 |
0.368 |
|
| 2003 |
Hruby G, Barton M, Miles S, Carroll S, Nasser E, Stevens G. Sites of local recurrence after surgery, with or without chemotherapy, for rectal cancer: implications for radiotherapy field design. International Journal of Radiation Oncology, Biology, Physics. 55: 138-43. PMID 12504046 DOI: 10.1016/S0360-3016(02)03812-9 |
0.335 |
|
| 2003 |
Delaney G, Jacob S, Barton M. O-120 Estimating an optimal radiotherapy utilisation rate for lung cancer based upon evidence-based treatment guidelines Lung Cancer. 41. DOI: 10.1016/S0169-5002(03)91778-8 |
0.345 |
|
| 2002 |
Delaney G, Jalaludin B, Moylan E, Barton M. The development of a model of outpatient chemotherapy delivery--chemotherapy basic treatment equivalent (CBTE). Clinical Oncology (Royal College of Radiologists (Great Britain)). 14: 406-12. PMID 12555880 DOI: 10.1053/Clon.2002.0141 |
0.319 |
|
| 2002 |
Kenny L, Peters L, Rodger A, Barton M, Turner S. Modern radiotherapy for modern surgeons: an update on radiation oncology. Anz Journal of Surgery. 72: 131-6. PMID 12074065 DOI: 10.1046/J.1440-1622.2002.02328.X |
0.351 |
|
| 2001 |
Tynan K, Barton M, Kricker W. Area Cancer Control Network: From cottage industry to strategic care. New South Wales Public Health Bulletin. 12: 266-269. PMID 12105433 DOI: 10.1071/Nb01089 |
0.322 |
|
| 2000 |
Barton M. Radiotherapy utilization in New South Wales from 1996 to 1998. Journal of Medical Imaging and Radiation Oncology. 44: 308-314. PMID 10974725 DOI: 10.1046/J.1440-1673.2000.00833.X |
0.38 |
|
| 1996 |
Barton M, Boyages J, Crennan E, Davis S, Fisher RJ, Hook C, Johnson N, Joseph D, Khoo V, Liew KH, Morgan G, O'Brien P, Pendlebury S, Pratt G, Quong G, et al. Radiotherapy for early infradiaphragmatic Hodgkin's disease: the Australasian experience. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 39: 1-7. PMID 8735487 DOI: 10.1016/0167-8140(96)01715-X |
0.314 |
|
| 1996 |
Zalcberg JR, Friedlander ML, Collopy BT, Barton M, Gray B. Treatment principles in advanced colorectal cancer Australian and New Zealand Journal of Surgery. 66: 202-205. PMID 8611124 DOI: 10.1111/J.1445-2197.1996.Tb01164.X |
0.367 |
|
| 1995 |
Barton M, Boyages J, Crennan E, Davis S, Fisher RJ, Hook C, Johnson N, Joseph D, Liew KH, Morgan G. Radiation therapy for early stage Hodgkin's disease: Australasian patterns of care. Australasian Radiation Oncology Lymphoma Group. International Journal of Radiation Oncology, Biology, Physics. 31: 227-36. PMID 7836074 DOI: 10.1016/0360-3016(94)E0261-H |
0.362 |
|
| 1995 |
O'Brien PC, Barton MB, Fisher R. Breast cancer following treatment for Hodgkin's disease: The need for screening in a young population Australasian Radiology. 39: 271-276. PMID 7487764 DOI: 10.1111/J.1440-1673.1995.Tb00291.X |
0.308 |
|
| 1992 |
Fyles A, Keane TJ, Barton M, Simm J. The Effect of Treatment Duration in the Local Control of Cervix Cancer Radiotherapy and Oncology. 25: 273-279. PMID 1480773 DOI: 10.1016/0167-8140(92)90247-R |
0.323 |
|
| Show low-probability matches. |
